Date Posted:


Zeus Capital acts as Nominated Adviser and Broker to C4X Discovery Holdings plc on its £5m fundraise

6th September 2016

Zeus Capital has acted as Nominated Adviser and Broker to C4X Discovery on its £5m institutional fundraise.

C4X Discovery aims to become the world’s most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. Since the Company’s successful AIM IPO in October 2014, C4X Discovery has made considerable progress across its in-house pipeline in addiction, diabetes and inflammation with a number of new drug candidates identified and further progress made towards the clinic. C4X Discovery now has five therapeutic projects underway.


The Company has two proprietary and synergistic software platforms, “Taxonomy3®” and “Conformetrix”, that provide a significant competitive advantage when combined with an experienced management team. “Taxonomy3®” is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. “Conformetrix” determines the 3D shape of drug molecules from experimental in vitro data giving medicinal chemists new and unprecedented insights into the behaviour and physical properties of drug molecules. This enables the rapid design and discovery of better and safer drugs for diseases with high unmet medical need across broad therapeutic areas. C4X Discovery’s drug discovery engine was further strengthened by the acquisition of technologies from Molplex Ltd, in 2016, which included a software-based system which combines chemoinformatics, computational chemistry and artificial intelligence to optimise the drug discovery process.


Clive Dix, CEO of C4X Discovery, commented: “The completion of this fundraise will allow C4X Discovery to continue on its path to becoming the world’s most productive drug discovery engine. We are already exploiting cutting edge-technologies to design and create best-in-class small molecule candidates. The additional funds will allow us to progress our existing innovative pipeline towards the clinic and draw on the strengths of our discovery engine to start the development of four new medicines for diseases with a high unmet medical need.

 “I am delighted to welcome Calculus and Polar Capital as new shareholders and would like to thank our existing investors that also took part in the Placing. We are extremely excited about the future at C4X Discovery.”


Dominic Wilson, Head of Healthcare Sales, Zeus Capital commented: “We are delighted to help secure £5m of new capital for C4X Discovery, attracting specialist healthcare investors to the shareholder register alongside support from existing holders. This successful funding is a clear endorsement of the progress the C4X team has made since IPO.”